StockRunway.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
New York, NY -- (SBWIRE) -- 02/19/2013 -- StockRunway.com issues special report on the Biotech Stocks – Peregrine Pharmaceuticals (NASDAQ:PPHM), Gilead Sciences, Inc. (NASDAQ:GILD), Dendreon Corporation (NASDAQ:DNDN) and MannKind Corporation (NASDAQ:MNKD)
Peregrine Pharmaceuticals (NASDAQ:PPHM) reported data from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer. Modernized results from this Phase II trial show an expressive progress in median overall persistence of 11.7 months in the 3mg/kg bavituximab + docetaxel arm compared to 7.3 months.
Can Investors Bet on PPHM after this News update? Find out in this Research Report
In the mid-day, Peregrine Pharmaceuticals (NASDAQ:PPHM) jumped +0.55% to $1.85 with the total traded volume of 4.69 million shares. Stock price 52 weeks high was $5.50 and 52 weeks low price was $0.39.
Gilead Sciences, Inc. (NASDAQ:GILD) recently declared a voluntary recall of one of its products, Vistide® (cidofovir injection), lot # B120217A, due to the existence of particulate stuff found in some flasks of this portion. The product portrayal is as follows, Vistide® – cidofovir injection, NDC # 61958-0101-1, Lot # B120217A, Expiration Date May 2015.
Is GILD a Solid Investment at These Levels? Read This Report For Details
During the mid-day trading, Gilead Sciences, Inc. (NASDAQ:GILD) soared +2.15% to $42.50 with the total traded volume of 3.98 million shares. GILD has earnings per share of $1.63 and its price to earnings ratio ended at 26.03.
Dendreon Corporation (NASDAQ:DNDN) shares were downgraded by Maxim group from “hold” to “sell” last week.
How Should Investors Trade DNDN Now? Don’t Miss out a Special Trend Analysis
In the mid-day trading hours, Dendreon Corporation (NASDAQ:DNDN) declined 2.28% to $5.93 with the total traded volume of 2.84 million shares. Its fifty two week range was $3.69-$15.20. The total market capitalization remained $914.61 million. DNDN is ahead its 52 week low with 61.36% and its last month price volatility remained 6.18%. Its beta coefficient was 3.89 with a target price of $6.24. DNDN has insider ownership of 2.86% with its institutional ownership remained 62.39%. Company’s current year earnings per share grew with 27.32% while the five year EPS growth rate was +12.65%.
MannKind Corporation (NASDAQ:MNKD) moved up +2.02% to $2.53 during the mid-day trading hours with the total traded volume of 1.63 million shares. MNKD has market cap of 624.27 million shares. Stock price 52 weeks high was $3.11 and 52 weeks low price was $1.57.
What MNKD’s Charts Are Signaling for Traders? Find Out Here
StockRunway.com is an Elite Financial Stock website catering to individual investors, fund managers, investment bankers and equity analysts. Whether you&aposre new to penny stocks or a seasoned veteran, you&aposll find all the information you will need right here! Our research is a remarkable educational tool for everyone to utilize.
Sign up TODAY and join the vast amount of investors already benefiting from the best free alerts from StockRunway&aposs service today!
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site, Press Releases or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Read our Full Disclaimer by visiting our website.
For more information on this press release visit: http://www.sbwire.com/press-releases/biotech-news-roundup-peregrine-pharmaceuticals-nasdaqpphm-gilead-sciences-dendreon-corp-mannkind-corp-209489.htm